Table 13.3GRADE evidence summary: Typical antipsychotics vs placebo /no treatment

Outcome/(Author (year)analysis detailsSummary statisticsCommentsGRADE detailsGRADE Comments
Complete response
(Hu 2006)
1 trial; 101 patients; from RCTRR=3.95 (95%CI 1.75, 8.9)Statistically significant improvement of delirium in the haloperidol group on clinical global impression scale at 7 days It is unlikely pts blinded because of nature of the interventions (IM vs control); Clinical global impression scale-indirect method of assessment of delirium; Both groups received somatic treatment aiming at delirium Large effect
GRADE evidence rating: Moderate
Duration of delirium
(Hu 2006)
1 trial; 101 patients; from RCTMD=−1.78 (95%CI − 2.86, − 0.7)Statistically significant shorter duration for the haloperidol group Reported on “time to take effect”: Duration of delirium was given for responder so potency biased
GRADE evidence rating: Very low
Severity delirium
(Hu 2006)
1 trial; 101 patients; from RCTMD=−10.4 (95%CI −13.95, −6.85)Statistically significant severity lower in the haloperidol group on the DRS (0–32)
  • Study quality: serious limitation not blinded
  • Directness: Direct
  • Imprecision: Number of patients < 400
  • Inconsistency: consistent
  • Reporting bias: Adequate
DRS scale 0–32, MID (20% = 6.4), i.e. CI precise, but fairly small number patients. Patients not blinded. Large effect
GRADE evidence rating: Moderate

From: 13, Treatment of delirium: pharmacological

Cover of Delirium
Delirium: Diagnosis, Prevention and Management [Internet].
NICE Clinical Guidelines, No. 103.
National Clinical Guideline Centre (UK).
Copyright © 2010, National Clinical Guideline Centre - Acute and Chronic Conditions.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.